Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 1.09
MDT's Cash to Debt is ranked higher than
65% of the 395 Companies
in the Global Medical Devices industry.

( Industry Median: 1.73 vs. MDT: 1.09 )
MDT' s 10-Year Cash to Debt Range
Min: 0.15   Max: 9.58
Current: 1.09

0.15
9.58
Equity to Asset 0.51
MDT's Equity to Asset is ranked higher than
60% of the 377 Companies
in the Global Medical Devices industry.

( Industry Median: 0.63 vs. MDT: 0.51 )
MDT' s 10-Year Equity to Asset Range
Min: 0.48   Max: 0.82
Current: 0.51

0.48
0.82
Interest Coverage 10.06
MDT's Interest Coverage is ranked higher than
50% of the 213 Companies
in the Global Medical Devices industry.

( Industry Median: 155.63 vs. MDT: 10.06 )
MDT' s 10-Year Interest Coverage Range
Min: 6.58   Max: 352.69
Current: 10.06

6.58
352.69
F-Score: 4
Z-Score: 4.22
M-Score: -2.68
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 21.31
MDT's Operating margin (%) is ranked higher than
93% of the 385 Companies
in the Global Medical Devices industry.

( Industry Median: 6.93 vs. MDT: 21.31 )
MDT' s 10-Year Operating margin (%) Range
Min: 16.71   Max: 66.79
Current: 21.31

16.71
66.79
Net-margin (%) 17.35
MDT's Net-margin (%) is ranked higher than
92% of the 385 Companies
in the Global Medical Devices industry.

( Industry Median: 5.11 vs. MDT: 17.35 )
MDT' s 10-Year Net-margin (%) Range
Min: 11.03   Max: 22.78
Current: 17.35

11.03
22.78
ROE (%) 15.65
MDT's ROE (%) is ranked higher than
91% of the 380 Companies
in the Global Medical Devices industry.

( Industry Median: 5.73 vs. MDT: 15.65 )
MDT' s 10-Year ROE (%) Range
Min: 14.54   Max: 32.99
Current: 15.65

14.54
32.99
ROA (%) 8.10
MDT's ROA (%) is ranked higher than
86% of the 395 Companies
in the Global Medical Devices industry.

( Industry Median: 3.49 vs. MDT: 8.10 )
MDT' s 10-Year ROA (%) Range
Min: 8.42   Max: 23.74
Current: 8.1

8.42
23.74
ROC (Joel Greenblatt) (%) 59.79
MDT's ROC (Joel Greenblatt) (%) is ranked higher than
95% of the 394 Companies
in the Global Medical Devices industry.

( Industry Median: 12.42 vs. MDT: 59.79 )
MDT' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 44.45   Max: 153.66
Current: 59.79

44.45
153.66
Revenue Growth (%) 5.40
MDT's Revenue Growth (%) is ranked higher than
74% of the 308 Companies
in the Global Medical Devices industry.

( Industry Median: 5.40 vs. MDT: 5.40 )
MDT' s 10-Year Revenue Growth (%) Range
Min: 4.2   Max: 17.9
Current: 5.4

4.2
17.9
EBITDA Growth (%) 3.50
MDT's EBITDA Growth (%) is ranked higher than
78% of the 282 Companies
in the Global Medical Devices industry.

( Industry Median: -1.20 vs. MDT: 3.50 )
MDT' s 10-Year EBITDA Growth (%) Range
Min: -15.5   Max: 45.4
Current: 3.5

-15.5
45.4
EPS Growth (%) 2.30
MDT's EPS Growth (%) is ranked higher than
76% of the 273 Companies
in the Global Medical Devices industry.

( Industry Median: 1.70 vs. MDT: 2.30 )
MDT' s 10-Year EPS Growth (%) Range
Min: -4.7   Max: 27.1
Current: 2.3

-4.7
27.1
» MDT's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

MDT Guru Trades in Q4 2013

Scott Black 41,683 sh (+193.58%)
Ray Dalio 132,345 sh (+190.58%)
Paul Tudor Jones 32,191 sh (+129.94%)
Jim Simons 1,512,400 sh (+47.31%)
John Hussman 250,000 sh (+21.95%)
Chuck Royce 133,200 sh (+18.09%)
Steven Cohen 18,543 sh (+13.69%)
John Buckingham 18,507 sh (+5.93%)
Pioneer Investments 877,947 sh (+3.94%)
James Barrow 32,642,450 sh (+0.98%)
Jeremy Grantham 10,186,365 sh (+0.62%)
John Keeley 34,160 sh (+0.12%)
Bill Frels 4,090,802 sh (+0.06%)
Jeff Auxier 151,720 sh (unchged)
Jean-Marie Eveillard 8,000 sh (unchged)
Bill Nygren 4,385,000 sh (unchged)
Vanguard Health Care Fund 10,532,800 sh (unchged)
HOTCHKIS & WILEY 1,740,800 sh (-0.49%)
PRIMECAP Management 31,614,803 sh (-0.72%)
Diamond Hill Capital 5,272,970 sh (-0.76%)
Ken Fisher 7,020 sh (-4.97%)
Dodge & Cox 9,019,976 sh (-5.96%)
Manning & Napier Advisors, Inc 202,619 sh (-43.94%)
Arnold Van Den Berg 133,283 sh (-49.89%)
Joel Greenblatt 90,485 sh (-53.27%)
» More
Q1 2014

MDT Guru Trades in Q1 2014

Steven Cohen 153,212 sh (+726.25%)
Joel Greenblatt 244,649 sh (+170.38%)
HOTCHKIS & WILEY 2,066,800 sh (+18.73%)
Vanguard Health Care Fund 11,336,900 sh (+7.63%)
Bill Nygren 4,585,000 sh (+4.56%)
Scott Black 43,053 sh (+3.29%)
John Buckingham 18,828 sh (+1.73%)
Diamond Hill Capital 5,349,218 sh (+1.45%)
Bill Frels 4,124,297 sh (+0.82%)
Manning & Napier Advisors, Inc 203,440 sh (+0.41%)
John Keeley 34,160 sh (unchged)
John Hussman 250,000 sh (unchged)
Arnold Van Den Berg Sold Out
Jean-Marie Eveillard Sold Out
PRIMECAP Management 31,570,188 sh (-0.14%)
Jim Simons 1,507,100 sh (-0.35%)
Dodge & Cox 8,982,143 sh (-0.42%)
Jeff Auxier 150,720 sh (-0.66%)
Ken Fisher 6,853 sh (-2.38%)
James Barrow 31,718,209 sh (-2.83%)
Chuck Royce 128,800 sh (-3.3%)
Pioneer Investments 809,321 sh (-7.82%)
Jeremy Grantham 7,050,459 sh (-30.79%)
Ray Dalio 87,345 sh (-34%)
Paul Tudor Jones 11,100 sh (-65.52%)
» More
Q2 2014

MDT Guru Trades in Q2 2014

Robert Olstein 115,000 sh (New)
Mario Gabelli 40,000 sh (New)
Jean-Marie Eveillard 2,098,343 sh (New)
Jim Simons 2,312,700 sh (+53.45%)
Pioneer Investments 1,113,090 sh (+37.53%)
Vanguard Health Care Fund 12,402,000 sh (+9.39%)
James Barrow 32,340,234 sh (+1.96%)
John Buckingham 19,010 sh (+0.97%)
Bill Frels 4,146,152 sh (+0.53%)
Bill Nygren 4,605,000 sh (+0.44%)
Steven Cohen 933,000 sh (unchged)
Steven Cohen 250,000 sh (unchged)
John Hussman Sold Out
Ray Dalio Sold Out
Manning & Napier Advisors, Inc Sold Out
Scott Black 42,983 sh (-0.16%)
Jeff Auxier 149,320 sh (-0.93%)
John Keeley 33,460 sh (-2.05%)
Dodge & Cox 8,776,593 sh (-2.29%)
Paul Tudor Jones 10,500 sh (-5.41%)
PRIMECAP Management 29,602,228 sh (-6.23%)
HOTCHKIS & WILEY 1,932,500 sh (-6.5%)
Ken Fisher 6,015 sh (-12.23%)
Diamond Hill Capital 4,605,630 sh (-13.9%)
Jeremy Grantham 5,518,126 sh (-21.73%)
Chuck Royce 66,100 sh (-48.68%)
Joel Greenblatt 9,398 sh (-96.16%)
» More
Q3 2014

MDT Guru Trades in Q3 2014

Vanguard Health Care Fund 12,402,000 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with MDT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Hussman 2014-06-30 Sold Out 1.2%$58.05 - $64.67 $ 68.1612%0
Robert Olstein 2014-06-30 New Buy0.99%$58.05 - $64.67 $ 68.1612%115000
Jean-Marie Eveillard 2014-06-30 New Buy0.32%$58.05 - $64.67 $ 68.1612%2098343
Joel Greenblatt 2014-06-30 Reduce -96.16%0.22%$58.05 - $64.67 $ 68.1612%9398
Vanguard Health Care Fund 2014-06-30 Add 9.39%0.18%$58.05 - $64.67 $ 68.1612%12402000
PRIMECAP Management 2014-06-30 Reduce -6.23%0.14%$58.05 - $64.67 $ 68.1612%29602228
Ray Dalio 2014-06-30 Sold Out 0.04%$58.05 - $64.67 $ 68.1612%0
Mario Gabelli 2014-06-30 New Buy0.01%$58.05 - $64.67 $ 68.1612%40000
Arnold Van Den Berg 2014-03-31 Sold Out 0.72%$53.6 - $60.84 $ 68.1617%0
Joel Greenblatt 2014-03-31 Add 170.38%0.14%$53.6 - $60.84 $ 68.1617%244649
Vanguard Health Care Fund 2014-03-31 Add 7.63%0.14%$53.6 - $60.84 $ 68.1617%11336900
Ray Dalio 2014-03-31 Reduce -34%0.02%$53.6 - $60.84 $ 68.1617%87345
Jean-Marie Eveillard 2014-03-31 Sold Out $53.6 - $60.84 $ 68.1617%0
Arnold Van Den Berg 2013-12-31 Reduce -49.89%0.7%$52.46 - $58.84 $ 68.1620%133283
Joel Greenblatt 2013-12-31 Reduce -53.27%0.18%$52.46 - $58.84 $ 68.1620%90485
John Hussman 2013-12-31 Add 21.95%0.18%$52.46 - $58.84 $ 68.1620%250000
Scott Black 2013-12-31 Add 193.58%0.17%$52.46 - $58.84 $ 68.1620%41683
Ray Dalio 2013-12-31 Add 190.58%0.04%$52.46 - $58.84 $ 68.1620%132345
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Medtronic Inc

Bill Frels Comments on Medtronic Inc - Oct 20, 2014

Healthcare company Medtronic, Inc. (MDT) detracted slightly from performance during the period. Pending a shareholder vote later this year or in 2015, Medtronic is expected to merge with medical device supplier Covidien Plc and change its legal domicile to Ireland. Your Growth Fund portfolio managers are pleased to report that we have completed our valuation for Medtronic. As of October 7, 2014 we believe combined Medtronic/Covidien to be $8 per share more valuable than shares of Medtronic alone.

As of September 30, 2014, the market value of the Growth Fund’s holding in Medtronic was $24 per share greater than its cost basis. We estimate that our typical shareholder, that holds the Growth Fund in a taxable amount, will experience about a $6.00 per share tax liability. We do not offer tax advice; each shareholder should consult a tax advisor about his/her particular circumstance. Providing that there are no significant changes, our current thinking leads us to believe that voting for the merger is in our shareholders’ best interest. We will keep you posted as the voting date is finalized or if we learn of any other developments regarding the merger plans.

From Bill Frels (Trades, Portfolio)' Mairs & Power Growth Fund Q3 2014 Commentary.

Check out Bill Frels latest stock trades

Bill Frels Comments on Medtronic Inc - Jul 31, 2014

Healthcare company Medtronic, Inc. (MDT) also contributed to performance, gaining 3.61% and 11.10% for the second quarter and first six months, respectively. Pending a shareholder vote later this year or in 2015, however, Medtronic is expected to merge with medical device supplier Covidien Plc and change its legal domicile to Ireland. Once completed, the merger will create a taxable event for Fund shareholders who will realize a long-term capital gain estimated at $60 million or $1.50 a share.

From Bill Frels (Trades, Portfolio)’ Mairs & Power Growth Fund Second Quarter 2014 Commentary.

Check out Bill Frels latest stock trades

Bill Frels Comments on Medtronic Inc - Jun 25, 2014

Healthcare company Medtronic, Inc. (MDT) also finished the quarter as a top five contributor to the Fund, gaining 7.23%. While emerging market revenue proved scarce for most industries during the quarter, Medtronic increased its share of revenue from the developing world by 15%, which represented 12% of the company’s revenue.



From Bill Frels' Mairs & Power Balance Fund First Quarter 2014 Commentary.



Check out Bill Frels latest stock trades

Top Ranked Articles about Medtronic Inc

Bill Frels Comments on Medtronic Inc
Healthcare company Medtronic, Inc. (MDT) detracted slightly from performance during the period. Pending a shareholder vote later this year or in 2015, Medtronic is expected to merge with medical device supplier Covidien Plc and change its legal domicile to Ireland. Your Growth Fund portfolio managers are pleased to report that we have completed our valuation for Medtronic. As of October 7, 2014 we believe combined Medtronic/Covidien to be $8 per share more valuable than shares of Medtronic alone. Read more...
Bill Frels Comments on Medtronic Inc
Healthcare company Medtronic, Inc. (MDT) also contributed to performance, gaining 3.61% and 11.10% for the second quarter and first six months, respectively. Pending a shareholder vote later this year or in 2015, however, Medtronic is expected to merge with medical device supplier Covidien Plc and change its legal domicile to Ireland. Once completed, the merger will create a taxable event for Fund shareholders who will realize a long-term capital gain estimated at $60 million or $1.50 a share. Read more...
Bill Frels Comments on Medtronic Inc
Healthcare company Medtronic, Inc. (MDT) also finished the quarter as a top five contributor to the Fund, gaining 7.23%. While emerging market revenue proved scarce for most industries during the quarter, Medtronic increased its share of revenue from the developing world by 15%, which represented 12% of the company’s revenue. Read more...
Bill Frels' Mairs & Power Balance Fund First Quarter 2014 Commentary
March 31, 2014 Read more...
Diamond Hill Capital's Top Five Holdings
Over the past quarter Diamond Hill Capital added seven new stocks to its portfolio, bringing the total number of stocks to 152 valued at $10.96 billion. The fund manages five long-only equity strategies, three alternative equity strategies and a fixed income strategy. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 23.10
MDT's P/E(ttm) is ranked higher than
88% of the 418 Companies
in the Global Medical Devices industry.

( Industry Median: 51.70 vs. MDT: 23.10 )
MDT' s 10-Year P/E(ttm) Range
Min: 10.14   Max: 43.51
Current: 23.1

10.14
43.51
P/B 3.53
MDT's P/B is ranked higher than
69% of the 418 Companies
in the Global Medical Devices industry.

( Industry Median: 3.38 vs. MDT: 3.53 )
MDT' s 10-Year P/B Range
Min: 2.03   Max: 7.06
Current: 3.53

2.03
7.06
P/S 4.00
MDT's P/S is ranked higher than
63% of the 418 Companies
in the Global Medical Devices industry.

( Industry Median: 3.06 vs. MDT: 4.00 )
MDT' s 10-Year P/S Range
Min: 1.92   Max: 7.25
Current: 4

1.92
7.25
PFCF 17.84
MDT's PFCF is ranked higher than
93% of the 418 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. MDT: 17.84 )
MDT' s 10-Year PFCF Range
Min: 9.2   Max: 70.14
Current: 17.84

9.2
70.14
EV-to-EBIT 17.88
MDT's EV-to-EBIT is ranked higher than
87% of the 418 Companies
in the Global Medical Devices industry.

( Industry Median: 34.56 vs. MDT: 17.88 )
MDT' s 10-Year EV-to-EBIT Range
Min: 8.8   Max: 23.8
Current: 17.88

8.8
23.8
PEG 7.97
MDT's PEG is ranked higher than
89% of the 418 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. MDT: 7.97 )
MDT' s 10-Year PEG Range
Min: 1.06   Max: 19.93
Current: 7.97

1.06
19.93
Shiller P/E 22.13
MDT's Shiller P/E is ranked higher than
94% of the 418 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. MDT: 22.13 )
MDT' s 10-Year Shiller P/E Range
Min: 12.16   Max: 52.2
Current: 22.13

12.16
52.2
Current Ratio 3.82
MDT's Current Ratio is ranked higher than
80% of the 395 Companies
in the Global Medical Devices industry.

( Industry Median: 2.70 vs. MDT: 3.82 )
MDT' s 10-Year Current Ratio Range
Min: 0.88   Max: 4.52
Current: 3.82

0.88
4.52
Quick Ratio 3.48
MDT's Quick Ratio is ranked higher than
83% of the 395 Companies
in the Global Medical Devices industry.

( Industry Median: 2.01 vs. MDT: 3.48 )
MDT' s 10-Year Quick Ratio Range
Min: 0.66   Max: 4.09
Current: 3.48

0.66
4.09

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.72
MDT's Dividend Yield is ranked higher than
69% of the 183 Companies
in the Global Medical Devices industry.

( Industry Median: 1.26 vs. MDT: 1.72 )
MDT' s 10-Year Dividend Yield Range
Min: 0.56   Max: 2.93
Current: 1.72

0.56
2.93
Dividend Payout 0.39
MDT's Dividend Payout is ranked higher than
85% of the 418 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. MDT: 0.39 )
MDT' s 10-Year Dividend Payout Range
Min: 0.13   Max: 2.04
Current: 0.39

0.13
2.04
Dividend growth (3y) 7.60
MDT's Dividend growth (3y) is ranked higher than
77% of the 104 Companies
in the Global Medical Devices industry.

( Industry Median: 10.10 vs. MDT: 7.60 )
MDT' s 10-Year Dividend growth (3y) Range
Min: 7.6   Max: 28.4
Current: 7.6

7.6
28.4
Yield on cost (5-Year) 2.50
MDT's Yield on cost (5-Year) is ranked higher than
72% of the 186 Companies
in the Global Medical Devices industry.

( Industry Median: 1.52 vs. MDT: 2.50 )
MDT' s 10-Year Yield on cost (5-Year) Range
Min: 0.82   Max: 4.31
Current: 2.5

0.82
4.31
Share Buyback Rate 2.10
MDT's Share Buyback Rate is ranked higher than
94% of the 287 Companies
in the Global Medical Devices industry.

( Industry Median: -0.90 vs. MDT: 2.10 )
MDT' s 10-Year Share Buyback Rate Range
Min: 2.6   Max: -8.5
Current: 2.1

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 10.92
MDT's Price/Tangible Book is ranked higher than
59% of the 418 Companies
in the Global Medical Devices industry.

( Industry Median: 6.00 vs. MDT: 10.92 )
MDT' s 10-Year Price/Tangible Book Range
Min: 7.26   Max: 44.29
Current: 10.92

7.26
44.29
Price/DCF (Projected) 1.18
MDT's Price/DCF (Projected) is ranked higher than
94% of the 418 Companies
in the Global Medical Devices industry.

( Industry Median: 456.50 vs. MDT: 1.18 )
MDT' s 10-Year Price/DCF (Projected) Range
Min: 0.77   Max: 6.95
Current: 1.18

0.77
6.95
Price/Median PS Value 1.13
MDT's Price/Median PS Value is ranked higher than
74% of the 418 Companies
in the Global Medical Devices industry.

( Industry Median: 1.13 vs. MDT: 1.13 )
MDT' s 10-Year Price/Median PS Value Range
Min: 0.66   Max: 3.57
Current: 1.13

0.66
3.57
Price/Peter Lynch Fair Value 3.63
MDT's Price/Peter Lynch Fair Value is ranked higher than
92% of the 418 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. MDT: 3.63 )
MDT' s 10-Year Price/Peter Lynch Fair Value Range
Min: 1.11   Max: 6.46
Current: 3.63

1.11
6.46
Price/Graham Number 3.32
MDT's Price/Graham Number is ranked higher than
78% of the 418 Companies
in the Global Medical Devices industry.

( Industry Median: 7.03 vs. MDT: 3.32 )
MDT' s 10-Year Price/Graham Number Range
Min: 2.1   Max: 11.15
Current: 3.32

2.1
11.15
Earnings Yield (Greenblatt) 5.60
MDT's Earnings Yield (Greenblatt) is ranked higher than
86% of the 391 Companies
in the Global Medical Devices industry.

( Industry Median: 3.50 vs. MDT: 5.60 )
MDT' s 10-Year Earnings Yield (Greenblatt) Range
Min: 4.2   Max: 11.3
Current: 5.6

4.2
11.3
Forward Rate of Return (Yacktman) 10.72
MDT's Forward Rate of Return (Yacktman) is ranked higher than
88% of the 320 Companies
in the Global Medical Devices industry.

( Industry Median: 1.44 vs. MDT: 10.72 )
MDT' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 3.3   Max: 23.6
Current: 10.72

3.3
23.6

Business Description

Industry: Medical Devices » Medical Devices
Compare:SYK, SMA, ZMH, STJ, EW » details
Traded in other countries:MDT.Germany, MDT.Mexico
Medtronic, Inc., was incorporated as a Minnesota corporation in 1957. The Company is engaged in providing medical technology- alleviating pain, restoring health, and extending life for people. The Company develops, manufactures, and markets its medical devices in more than 140 countries. Its products include those for cardiac rhythm disorders, cardiovascular disease, neurological disorders, spinal conditions and musculoskeletal trauma, urological and digestive disorders, diabetes, and ear, nose, and throat conditions. The Company's operating segments are: Cardiac and Vascular Group; and Restorative Therapies Group. Cardiac and Vascular Group includes Cardiac Rhythm Disease Management (CRDM) and CardioVascular. Restorative Therapies Group includes Spinal, Neuromodulation, Diabetes, and Surgical Technologies. CRDM develops, manufactures, and markets products for the diagnosis, treatment, and management of heart rhythm disorders and heart failure, including implantable devices, leads and delivery systems, products for the treatment of atrial fibrillation (AF), and information systems for the management of patients with CRDM devices. CardioVascular is composed of the following three businesses: Coronary, Endovascular and Peripheral, and Structural Heart. Its Spinal business develops, manufactures, and markets a comprehensive line of medical devices and implants used in the treatment of the spine and musculoskeletal system. Its Neuromodulation business develops, manufactures, and markets medical devices for the treatment of chronic pain, movement disorders, psychological disorders, and urological, fecal, and gastroenterological disorders. Its Diabetes business develops, manufactures, and markets advanced, integrated diabetes management solutions that include insulin pump therapy, continuous glucose monitoring systems, and therapy management software. Its Surgical Technologies business develops, manufactures, and markets products and therapies to treat diseases and conditions of the ear, nose, and throat (ENT) and certain neurological disorders. In addition, the business develops, manufactures, and markets image-guided surgery and intra-operative imaging systems that facilitate surgical planning during precision cranial, spinal, sinus, and orthopedic surgeries. Its main customers include hospitals, clinics, third-party health care providers, distributors, and other institutions, including governmental health care programs and group purchasing organizations. Its competitors are St. Jude Medical, Inc., Boston Scientific Corporation, Biotronik, Inc., Sorin Group, Abbott Laboratories and Boston Scientific, GETINGE AB, and Terumo Medical Corporation. The Company's medical devices are subject to regulation by numerous government agencies, including the U.S.
» More Articles for MDT

Headlines

Articles On GuruFocus.com
Bill Frels Comments on Medtronic Inc Oct 20 2014 
EW: Potential for Capital Appreciation Oct 03 2014 
Medical Technology Company Offers Investment Opportunity Sep 25 2014 
Medtronic Inc. (MDT) Dividend Stock Analysis Sep 12 2014 
Paulson, Mindich and Soros Bought Covidien; Should You? Sep 11 2014 
Abbott: A Brighter Future Aug 28 2014 
Jeff Auxier Second Quarter Shareholder Letter Aug 08 2014 
Outlook for August 2014 Aug 01 2014 
Mairs & Power Balanced Fund Second Quarter 2014 Commentary Jul 31 2014 
Bill Frels Comments on Medtronic Inc Jul 31 2014 


More From Other Websites
MEDTRONIC INC Files SEC form 8-K, Other Events Oct 30 2014
Today's Market Thorns, Roses, and All Time Highs... Oct 29 2014
Medtronic Initiates Clinical Study on Latest Heart Valve Oct 29 2014
Medtronic, Inc. -- Moody's says Medtronic's ratings likely to fall to A3/Prime-2 Oct 29 2014
Medtronic Begins Global Clinical Study of Investigational Pericardial Surgical Aortic Heart Valve Oct 28 2014
Medtronic Begins Global Clinical Study of Investigational Pericardial Surgical Aortic Heart Valve Oct 28 2014
Unexpected Obamacare boost Oct 27 2014
EU mergers and takeovers (Oct 27) Oct 27 2014
Edwards Lifesciences Hits New High On Q3 Earnings Oct 24 2014
Brazil suitors increase bid for Chiquita Oct 23 2014
Insight - U.S. government probes medical devices for possible cyber flaws Oct 22 2014
Markets open for trading: AbbVie/Shire deal scrapped Oct 21 2014
Medtronic Launches the Divergence(TM) Anterior Cervical Fusion System Oct 21 2014
Medtronic Launches the Divergence(TM) Anterior Cervical Fusion System Oct 21 2014
Medtronic Announces Global Launch of Titanium-Coated Peek Interbody Fusion Devices Oct 20 2014
Medtronic Announces Global Launch of Titanium-Coated Peek Interbody Fusion Devices Oct 20 2014
Medtronic Initiates Enrollment for Pivotal Diabetes IDE Study Oct 16 2014
AbbVie sours on $55B Shire deal after tax changes Oct 16 2014
AbbVie sours on $55B Shire deal after tax changes Oct 16 2014
AbbVie board rejects tax-cutting inversion plan Oct 16 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK